Compare Stocks: ACBFF, RDY, CRNX, and ALKS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACBFF Aurora Cannabis	$2.99 +0.3%	$2.89	$2.20 ▼ $12.53	$2.87B	N/A	4.22 million shs	948,157 shs
ALKS Alkermes	$49.21 -0.4%	$49.58	$25.17 ▼ $55.67	$8.29B	0.34	1.76 million shs	1.37 million shs
CRNX Crinetics Pharmaceuticals	$84.36 +0.2%	$60.93	$27.51 ▼ $84.38	$8.93B	0.12	3.12 million shs	1.42 million shs
RDY Dr. Reddy's Laboratories	$12.47 +2.6%	$13.13	$11.36 ▼ $15.67	$10.14B	0.29	2.84 million shs	2.37 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACBFF Aurora Cannabis	0.00%	+7.17%	+10.33%	-12.57%	-33.26%
ALKS Alkermes	+0.47%	-0.26%	-4.89%	+29.02%	+84.95%
CRNX Crinetics Pharmaceuticals	+0.08%	+0.47%	+0.68%	+127.99%	+213.41%
RDY Dr. Reddy's Laboratories	-0.61%	+0.57%	-8.13%	-2.51%	-12.12%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACBFF Aurora Cannabis	$2.99 +0.3%	$2.89	$2.20 ▼ $12.53	$2.87B	N/A	4.22 million shs	948,157 shs
ALKS Alkermes	$49.21 -0.4%	$49.58	$25.17 ▼ $55.67	$8.29B	0.34	1.76 million shs	1.37 million shs
CRNX Crinetics Pharmaceuticals	$84.36 +0.2%	$60.93	$27.51 ▼ $84.38	$8.93B	0.12	3.12 million shs	1.42 million shs
RDY Dr. Reddy's Laboratories	$12.47 +2.6%	$13.13	$11.36 ▼ $15.67	$10.14B	0.29	2.84 million shs	2.37 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACBFF Aurora Cannabis	0.00%	+7.17%	+10.33%	-12.57%	-33.26%
ALKS Alkermes	+0.47%	-0.26%	-4.89%	+29.02%	+84.95%
CRNX Crinetics Pharmaceuticals	+0.08%	+0.47%	+0.68%	+127.99%	+213.41%
RDY Dr. Reddy's Laboratories	-0.61%	+0.57%	-8.13%	-2.51%	-12.12%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACBFF Aurora Cannabis	0.00	N/A	N/A	N/A
ALKS Alkermes	2.72	Moderate Buy	$54.56	10.88% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-3.98% Downside
RDY Dr. Reddy's Laboratories	1.67	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest ACBFF, RDY, CRNX, and ALKS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	ALKS Alkermes	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
7/30/2026	ALKS Alkermes	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
7/29/2026	ALKS Alkermes	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$60.00 ➝ $61.00
7/29/2026	ALKS Alkermes	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$48.00 ➝ $58.00
7/28/2026	ALKS Alkermes	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$43.00 ➝ $65.00
7/28/2026	CRNX Crinetics Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$55.00 ➝ $85.00
7/27/2026	CRNX Crinetics Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/23/2026	RDY Dr. Reddy's Laboratories	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold (C) ➝ Hold (C-)
7/20/2026	ALKS Alkermes	Stifel Nicolaus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$45.00 ➝ $63.00
7/17/2026	CRNX Crinetics Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/13/2026	ALKS Alkermes	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$61.00 ➝ $62.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	$1.48B	5.59	$1.68 per share	29.37	$11.02 per share	4.47
CRNX Crinetics Pharmaceuticals	$7.70M	1,162.09	N/A	N/A	$9.71 per share	8.69
RDY Dr. Reddy's Laboratories	$3.58B	2.91	$0.86 per share	14.43	$4.86 per share	2.56

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACBFF Aurora Cannabis	N/A	$0.12	24.92	N/A	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	$241.66M	$0.38	129.50	205.04	N/A	3.96%	4.15%	2.19%	10/28/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	N/A
RDY Dr. Reddy's Laboratories	$456M	$0.44	28.33	21.13	2.45	10.15%	9.49%	6.32%	10/23/2026 (Estimated)

Latest ACBFF, RDY, CRNX, and ALKS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million
5/12/2026	Q4 25/26	RDY Dr. Reddy's Laboratories	$0.09	$0.06	-$0.03	-$0.03	$886.58 million	$852.55 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACBFF Aurora Cannabis	N/A	N/A	N/A	N/A	N/A
ALKS Alkermes	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.48%	+6.96%	13.64%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACBFF Aurora Cannabis	N/A	N/A	N/A
ALKS Alkermes	0.82	2.30	1.85
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACBFF Aurora Cannabis	N/A
ALKS Alkermes	95.21%
CRNX Crinetics Pharmaceuticals	98.51%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
ACBFF Aurora Cannabis	N/A
ALKS Alkermes	4.59%
CRNX Crinetics Pharmaceuticals	3.80%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACBFF Aurora Cannabis	1,340	960.96 million	N/A	Not Optionable
ALKS Alkermes	2,050	167.76 million	160.06 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.07 million	102.04 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable

ACBFF, RDY, CRNX, and ALKS Headlines

Recent News About These Companies

Zacks Research Issues Pessimistic Outlook for RDY Earnings

August 11 at 8:27 AM | marketbeat.com

Arrowstreet Capital Limited Partnership Buys Shares of 102,643 Dr. Reddy's Laboratories Ltd $RDY

August 6, 2026 | marketbeat.com

Dr. Reddy's Laboratories Launches Sugammadex Injection Single-Dose Vials in US

August 5, 2026 | finance.yahoo.com

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

August 5, 2026 | globenewswire.com

Dr. Reddy's Laboratories Ltd $RDY Shares Purchased by Quantinno Capital Management LP

August 5, 2026 | marketbeat.com

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of ...

August 4, 2026 | finance.yahoo.com

Sei Investments Co. Increases Stock Position in Dr. Reddy's Laboratories Ltd $RDY

August 4, 2026 | marketbeat.com

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

August 4, 2026 | businesswire.com

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

July 31, 2026 | prnewswire.com

Royal Bank of Canada Buys 434,805 Shares of Dr. Reddy's Laboratories Ltd $RDY

July 31, 2026 | marketbeat.com

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Lazard Asset Management LLC

July 30, 2026 | marketbeat.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

July 29, 2026 | globenewswire.com

Dr Reddys Laboratories Ltd (RDY)

July 28, 2026 | insidermonkey.com

Dr Reddy's Laboratories Ltd (RDY) Q1 2027 Earnings Call Highlights: Navigating Challenges and ...

July 28, 2026 | finance.yahoo.com

RDY Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Dr. Reddy's Laboratories (RDY)

July 28, 2026 | businesswire.com

Renaissance Technologies LLC Sells 395,400 Shares of Dr. Reddy's Laboratories Ltd $RDY

July 26, 2026 | marketbeat.com

Dr. Reddy's Laboratories (NYSE:RDY) Downgraded by Wall Street Zen to Sell

July 25, 2026 | marketbeat.com

Dr. Reddy's Laboratories Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into Dr. Reddy's Laboratories (RDY)

July 24, 2026 | prnewswire.com

U.S. pharma tariffs 'can't be absorbed' and drug prices will increase, says Dr Reddy's CEO

July 24, 2026 | youtube.comY

U.S. to see higher generic drug prices thanks to tariffs, CEO of leading India pharma firm warns

July 23, 2026 | cnbc.com

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down

July 23, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACBFF, RDY, CRNX, and ALKS Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

$2.99 +0.01 (+0.34%)

As of 08/7/2026

Aurora Cannabis Inc is a Canada-based company engaged in the production and distribution of medical cannabis. The Company is vertically integrated and horizontally diversified across every key segment of the value chain, from facility engineering and design to cannabis breeding and genetics research, cannabis and hemp production, derivatives, home cultivation, wholesale and retail distribution. The Company's purpose-built facilities, which integrate technologies across all processes, are defined by automation and customization. The Company has a funded capacity of more than 500,000 kilograms per year, as well as sales and operations in more than 10 countries worldwide.

Alkermes NASDAQ:ALKS

$49.21 -0.19 (-0.38%)

Closing price 04:00 PM Eastern

Extended Trading

$50.26 +1.05 (+2.14%)

As of 07:56 PM Eastern

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.36 +0.21 (+0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$84.24 -0.12 (-0.14%)

As of 07:37 PM Eastern

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$12.46 +0.32 (+2.59%)

Closing price 03:59 PM Eastern

Extended Trading

$12.44 -0.02 (-0.16%)

As of 07:34 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACBFF, RDY, CRNX, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACBFF, RDY, CRNX, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACBFF, RDY, CRNX, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACBFF, RDY, CRNX, and ALKS Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ACBFF, RDY, CRNX, and ALKS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ACBFF, RDY, CRNX, and ALKS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ACBFF, RDY, CRNX, and ALKS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ACBFF, RDY, CRNX, and ALKS Company Descriptions

Aurora Cannabis OTCMKTS:ACBFF

Alkermes NASDAQ:ALKS

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools